David Dejardin

11PUBLICATIONS
118CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Stochastic analysis and modellingApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Mar 27, 2026
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors.

Maria Vieito, Elisa Fontana, Catherine H Han

|Nov 18, 2025
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors.

Ignacio Melero, Josep Tabernero, Neeltje Steeghs

|Sep 21, 2025
Bayesian generalized method of moments applied to pseudo-observations in survival analysis.

Léa Orsini, Caroline Brard, Emmanuel Lesaffre

|Feb 03, 2025
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.

Eva Munoz-Couselo, Ainara Soria Rivas, Shahneen Sandhu

|Oct 18, 2024
Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma.

Aaron R Hansen, Carlos A Gomez-Roca, Debbie G J Robbrecht

|May 06, 2024
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer.

Hans Prenen, Sanjeev Deva, Bhumsuk Keam

Pageof 2

Frequent Collaborators

7 joint publications

Volker Teichgräber

7 joint publications

Jehad Charo

6 joint publications

Stefan Evers

6 joint publications

Christophe Boetsch